Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Cancer treatment faces challenges with complex, heterogeneous, and multigenic tumors.
• Existing single-target tyrosine kinase inhibitors often lead to chemotherapy resistance.
• Tumor cell signal transduction pathways are key targets for novel antitumor agents.

Purpose of the Study:

• To review recent advancements in the discovery of multitargeted tyrosine kinase inhibitors (MT-TKIs).
• To summarize the chemical structures, kinase inhibitory, and antitumor activities of novel MT-TKIs.
• To discuss the structure-activity relationships (SARs) of promising MT-TKIs.

Main Methods:

• Literature review of recent scientific publications on MT-TKIs.
• Analysis of chemical structures and reported biological activities of identified compounds.
• Summarization of structure-activity relationship (SAR) data for promising MT-TKIs.

Main Results:

• MT-TKIs demonstrate potential therapeutic advantages over single-targeted inhibitors.
• Several promising MT-TKIs with significant kinase inhibitory and antitumor activity have been identified.
• Structure-activity relationship (SAR) studies provide insights into the design of effective MT-TKIs.

Conclusions:

• MT-TKIs represent a significant advancement in cancer therapy, offering a strategy to combat drug resistance.
• Further research into MT-TKIs based on their chemical structures is crucial for developing next-generation antitumor agents.
• Understanding SARs is key to optimizing the efficacy and safety of MT-TKIs.